Objective: The spectrum of risk factors for HIV-associated cognitive impairment is likely very broad and includes not only HIV/antiretroviral therapy-specific factors but also other comorbid conditions. The purpose of this current study was to explore possible determinants for decreased cognitive performance.
Introduction
With the introduction of combination antiretroviral therapy (cART), AIDS-associated mortality and morbidity have markedly diminished and HIV encephalopathy, previously known as AIDS dementia complex, has largely disappeared [1] [2] [3] . In the past few years, however, a high prevalence (15-69%) of milder forms of cognitive impairment has been reported among HIV-infected individuals, including those with systemically well controlled HIV infection [4] [5] [6] [7] [8] [9] .
To classify this broad clinical spectrum of HIV-associated neurocognitive disorders, a set of diagnostic criteria, commonly referred to as Frascati criteria, was developed [10] . These criteria, however, appear oversensitive, resulting in not only high prevalence estimates but also high false-positive rates. We recently reported multivariate normative comparison (MNC), a technique which controls the false-positive rate while retaining sensitivity, to be a more accurate method of detecting cognitive impairment in the HIV-infected population [11] .
In this previous report, we found cognitive impairment by MNC to be present in 17% of 103 HIV-infected men and in 5% of 74 HIV-uninfected controls participating in the AGE h IV Cohort Study (P ¼ 0.02, one-tailed). Applying Frascati criteria to the same study population, cognitive impairment was highly prevalent in HIVinfected participants (48%), but nearly equally so in HIV-uninfected controls (36%, P ¼ 0.09, one tailed), indicating a high-false positive rate [11] .
In the pre-cART era, HIV-specific factors such as HIV viral load and CD4 þ cell count were most strongly associated with cognitive impairment [12] . In cARTtreated (and aging) individuals, however, the relative contribution of other risk factors towards cognitive impairment, including cardiovascular, metabolic, and other comorbid conditions, is likely to gain relative importance besides HIV/ART-specific factors such as persistent immune activation and inflammation [13] . The relative contribution of each of such factors to the pathogenesis of cognitive impairment remains to be further elucidated.
The purpose of this current study was to explore possible determinants for decreased cognitive performance as determined by MNC in the same abovementioned AGE h IV Cohort Study population. Within this study, which investigates age-associated comorbidity among middle-aged individuals with and without HIV-1 infection, a nested substudy was established focusing on cognitive functioning. We performed cross-sectional analyses on these 103 HIV-1-infected and 74 HIVuninfected substudy participants, exploring a broad range of possible determinants for decreased cognitive performance including HIV/ART-related factors, inflammatory markers, use of illicit drugs and/or alcohol, psychiatric conditions, and metabolic and cardiovascular risk factors.
Methods

Study design and participants
The AGE h IV Cohort Study is a prospective cohort study investigating prevalence, incidence, and risk factors of ageing-associated comorbidities and organ dysfunction among HIV-1-infected individuals and highly comparable HIV-uninfected controls, aged at least 45, in Amsterdam, The Netherlands, the details of which have been previously described [14] .
At baseline, and every 2 years thereafter, participants undergo extensive screening for age-associated comorbidity and organ dysfunction.
All eligible participants from the main AGE h IV Cohort were consecutively invited to participate in a nested cognitive substudy, which began enrolment in December 2011 [11] . Additional eligibility criteria for the substudy were male sex (as the availability of native Dutch-speaking women in the main AGE h IV Cohort was limited), and for the HIV-1-infected group, sustained suppression of HIV-1 viraemia on antiretroviral treatment (plasma HIV-1 RNA <40 copies/ml) for at least 12 months; the presence of so-called viral 'blips' (transient low-level viraemia between 40 and 200 copies/ml) was not an exclusion criterion.
Exclusion criteria for the substudy were a history of severe neurological disorder [e.g. stroke, seizure disorders, multiple sclerosis, dementia (including previous or current diagnosis of HIV-associated dementia)], history of traumatic brain injury with loss of consciousness for more than 30 min, current/past (HIV-associated) central nervous system infection or tumour, current severe psychiatric disorder (e.g. psychosis and major depression), current intravenous drug use, daily use of illicit drugs (with the exception of daily cannabis use), current excessive alcohol consumption (>48 units of alcohol/ week), insufficient command of the Dutch language, and mental retardation. Individuals with a previous or current diagnosis of HIVassociated dementia were excluded from participation as they most likely already underwent interventions (e.g. adaptation of their antiretroviral treatment), biasing the results of our study.
With respect to major depression as one of the exclusion criteria, depressive symptoms were assessed in the main AGE h IV Cohort Study by the nine-item Patient Health Questionnaire. Participants with a nine-item Patient Health Questionnaire score of at least 15 (indicative of severe depressive symptoms and high risk of major depression) were excluded from the participation in the substudy [15] .
The inclusion/exclusion criteria with regard to illicit drug use (allowing weekly to monthly use of cocaine or ecstasy, as well as daily cannabis use) were implemented to minimize selection bias and were based on illicit drug use prevalence data previously obtained from the main AGE h IV Cohort. These showed daily cannabis use and weekly to monthly cocaine or ecstasy use to be fairly common among both HIV-1-infected participants attending the HIV outpatient department and HIV-uninfected controls [14] .
Standard protocol approvals, registrations, and patient consents
The protocol of the AGE h IV Cohort Study, including the abovementioned substudy, was approved by the local ethics committee and has been registered at www.clinicaltrials.gov (identifier: NCT01466582). Written informed consent was obtained from all participants, separately for the main cohort study and nested substudy.
Neuropsychological assessment
As part of the substudy, neuropsychological assessment was performed by trained neuropsychologists and covered six cognitive domains commonly affected by HIV-associated cognitive impairment, including fluency, attention, information processing speed, executive function, memory, and motor function (details are provided in a previous publication) [11] . Depressive symptoms were assessed using the Beck Depression Inventory [16] , and subjective cognitive complaints with the Cognitive Failures Questionnaire [17] . Everyday functioning was assessed using the Instrumental Activities of Daily Living [18] questionnaire and premorbid intelligence was estimated by the Dutch Adult Reading Test [19] . Use of psychotropic medication was assessed and included antidepressants, benzodiazepines, and methylphenidate.
Definitions
All definitions of investigated variables are provided as footnotes in Tables 1 and 2 .
Cognitive impairment diagnosis by multivariate normative comparison
MNC is a statistical method that may be seen as a multivariate version of Student's t test for one sample [11, 20] . MNC is able to control the family-wise error (the probability of falsely diagnosing individuals as cognitively abnormal) by performing a single multivariate comparison of the complete cognitive profile of a particular patient to the distribution of all the cognitive profiles of the control sample, rather than comparing each test result separately to the reference population. The term 'MSM' applied to male participants who stated in the questionnaire to feel mostly or exclusively sexually attracted to men. b Duration of undetectable plasma viral load was defined as: number of years since last plasma viral load >200 copies/ml. c The term 'cART' was used for a combination of !3 antiretroviral drugs, other than ritonavir used as a pharmacologic booster. Table 2 . Baseline characteristics related to cognition, behaviour, comorbidity, and inflammation.
HIV uninfected (n ¼
74)
HIV-1 infected (n ¼ The variable past cardiovascular disease included angina pectoris, myocardial infarction, and peripheral arterial disease diagnoses, each being reported by the participants in a questionnaire. All selfreported diagnoses were then validated using hospital records for HIV positives, and general practitioners' records for HIV negatives, provided the latter had consented to contact their general practitioner. One HIV-uninfected participant did not provide consent to contact his general practitioner, resulting in one unconfirmed cardiovascular event. Further detail concerning diagnosis and validation of cardiovascular diseases has been previously reported [14] . MNC thus compares the complete cognitive profile of each HIV-1-infected participant with the cognitive profile of the HIV-uninfected control group as a whole. The test statistic is Hotelling's T 2 . The false positive rate, that is erroneously concluding that an individual deviates from the control sample while this is not the case, is limited by the level of significance (a). In the present study, a was set at 5% one tailed, resulting in a specificity of at least 95%, as confirmed in our previous publication [11] . In that previous report, the false-positive rate for cognitive impairment was shown to be much higher when applying Frascati criteria, and was greatly reduced by applying MNC, indicating MNC to be a very powerful and more accurate tool for detecting cognitive impairment.
Multivariate normative comparison: cognitive impairment as a dichotomous measure and cognitive performance as a continuous measure Applying MNC as described in the previous subsection provides a dichotomous result (cognitive impairment vs. no cognitive impairment). As the number of cognitively impaired participants in our cohort, as diagnosed by MNC, was relatively small, statistical power to investigate determinants was limited.
MNC, however, also provides a continuous measure: the Hotelling's T 2 statistic. The Hotelling's T 2 statistic reflects the degree of cognitive deviation of each HIV-1-infected participant compared with the HIV-uninfected control group as a whole.
The direction of the deviation (better or worse cognitive performance compared with the control population) was determined using the sum of all z-scores of the participant (being a positive or negative score). Hotelling's T 2 statistics were then transformed to a normal distribution by subtracting the lowest absolute Hotelling's T 2 statistic from all absolute Hotelling's T 2 statistics. This way the bimodal curve of the Hotelling's T 2 statistic was transformed to a curve with a single peak, approaching a normal distribution (as confirmed by skewness and kurtosis tests).
This continuous measure enabled us to perform more robust statistical analyses (linear instead of logistic regression) and increased statistical power. We therefore used this variable as the main outcome measure in the regression analyses.
Statistical analysis
Group comparisons were performed using the nonparametric test for trend, x 2 , Fisher's exact, or Wilcoxon rank-sum test as appropriate.
Determinants for decreased cognitive performance were analyzed by linear regression using the Hotelling's T 2 statistic from the MNC analysis as a continuous variable as outcome measure. As a sensitivity analysis, determinants for cognitive impairment as dichotomized by MNC, were analyzed by logistic regression. All regression analyses were restricted to the HIV-1-infected study group.
Plausible determinants of cognitive performance were analyzed using a forward stepwise model selection with P less than 0.05 as entry and P more than 0.1 as exit criterion, exploring the following categories of variables:
( 
Results
Participants' characteristics One hundred and three HIV-1-infected and 74 HIVuninfected men were consecutively enrolled into the substudy between December 2011 and August 2013. Demographic and HIV-related characteristics are shown in Table 1 . Both the groups were highly comparable, with a median age of 54 in both the groups, the majority of whom were MSM.
HIV-1-infected men were known to be infected and treated with antiretroviral medication for a prolonged period of time, and 35% had previously been diagnosed with AIDS. The majority had experienced substantial immune recovery on cART, with a median nadir CD4 þ cell count of 170 cells/ml, current median CD4 þ cell count of 625 cells/ml, and undetectable plasma viral load for a median 8 years.
Factors related to cognition, behaviour, comorbidity, and inflammation are presented in Table 2 . Both groups were comparable regarding native language, educational level, premorbid intelligence, depressive symptoms, and use of psychotropic medication. Smoking was more prevalent among HIV positives (30 vs. 19% currently smoking, P ¼ 0.048) and ecstasy use was more prevalent among HIV-uninfected controls (13 vs. 2%, P ¼ 0.008), whereas cannabis, cocaine, and alcohol use were comparable between the two groups. Among HIV-positives, BMI was significantly lower [24.1 (interquartile range, IQR, 22.2-26.0) vs. 25.4 (IQR 23.7 -27.5) kg/m 2 , P ¼ 0.003] and waist-to-hip ratio significantly higher [0.96 (IQR 0.92-1.01) vs. 0.93 (IQR 0.89-0.99), P ¼ 0.02]. Total, HDL, and LDL cholesterol, lipoprotein(a), and triglyceride levels were comparable between the two groups, as was use of lipid-lowering medication, physical activity, family history for metabolic/cardiovascular disease, history of cardiovascular disease, diabetes mellitus type 2, hypertension, and estimated glomerular filtration rate. Increased urinary albumin-to-creatinine ratio (!3 mg/ mmol) was significantly more prevalent among HIV positives (19.2 vs. 5.8%, P ¼ 0.01). Levels of hsCRP and sCD14 were significantly higher among HIV positives [1.5 (IQR 0.7-3.3) vs. 1.1 (IQR 0.6-2.1) mg/l, P ¼ 0.02 and 1548 (IQR 1318-2025) vs. 1207 (IQR 995-1558) ng/ml, P < 0.001, respectively]. hsCRP levels above 10 mg/l were also significantly more prevalent among HIV positives (10 vs. 0%, P ¼ 0.005). D-dimer and sCD163 levels were comparable between the two study groups.
Cognitive impairment as diagnosed by multivariate normative comparison
As previously reported, using MNC, cognitive impairment was detected in 17 (17%) HIV-1-infected men. Transformed Hotelling's T 2 statistics of the HIV-1infected men ranged between À2.39 and 1.90, with a median of À0.15 (IQR À0.87 to þ0.48).
Determinants of decreased cognitive performance by multivariate normative comparison in HIV-1-infected cohort participants
Linear regression analysis showed cannabis use, history of prior cardiovascular disease (borderline), impaired renal function (borderline), diabetes mellitus type 2, having an above-normal waist-to-hip ratio (borderline), presence of depressive symptoms (borderline), and lower nadir CD4 þ cell count to be independently associated with poorer cognitive performance ( Model 1 uses cognitive performance (as a continuous variable) as determined by MNC as outcome measure. Linear regression was performed to identify determinants for decreased cognitive performance. Model 2 uses cognitive impairment (as a dichotomous variable) as determined by MNC as outcome measure. Logistic regression was performed to identify determinants for cognitive impairment. Both the models were restricted to the HIV-1-infected study group. BDI, Beck depression inventory; 95% CI, 95% confidence interval; MNC, multivariable normative comparison. The waist-to-hip ratio was considered higher than normal if it was !0.9. e Depressive symptoms were considered present with a BDI score >13.
Determinants of cognitive impairment as dichotomized by multivariate normative comparison in HIV-1-infected cohort participants (sensitivity analysis) Logistic regression analysis showed cannabis use, history of prior cardiovascular disease, impaired renal function, and diabetes mellitus type 2 (borderline) to be independently associated with cognitive impairment ( Table 3 , Model 2).
Discussion
Key results
Determinants for decreased cognitive performance by MNC, when used as a continuous variable, included cannabis use, history of prior cardiovascular disease, impaired renal function, diabetes mellitus type 2, having an above-normal waist-to-hip ratio, presence of depressive symptoms, and lower nadir CD4 þ cell count.
The first four determinants were also observed in a sensitivity analysis for which cognitive impairment was dichotomized as being present or absent by MNC. The latter three variables were not significant determinants in this analysis.
Interpretation, limitations, and conclusion
To appreciate these findings, some aspects of the current report need to be addressed further. Strong features of the AGE h IV Cohort Study and its nested substudy are the large similarity between the HIV-1-infected and the HIV-uninfected study groups, as well as the high level of detail by which all participants have been characterized. In addition, extensive clinical and biochemical data were obtained allowing for detailed assessment of relationships and adjustment for confounding.
Our results being those of cross-sectional analyses, we are merely able to demonstrate associations rather than causality. Although the HIV-1-infected and HIV-uninfected study groups were largely comparable, differences in some demographic and lifestyle-related factors were present, which was addressed by exploring the effect of each factor towards cognitive (dys)function, and incorporating adjustment for those factors with a significant effect. Nonetheless, differences in remaining unmeasured confounders potentially influencing our results cannot be excluded.
In addition, some unique characteristics of this cohort (participants being mostly white middle-aged MSM with sustained viral suppression, with a low prevalence of chronic hepatitis B and C) may limit generalization of the results to other populations. Additional studies are needed to determine whether our findings apply equally to other populations with different characteristics.
When analyzing determinants of cognitive impairment/ performance by MNC, we found cannabis use to be strongly associated with cognitive dysfunction. Both in the general population and among HIV positives, cannabis use has been associated with decreased cognitive function [21, 22] . In the context of HIV infection, cannabis use is common, not only for recreational but also for medicinal use (treating neuropathic pain, anorexia, nausea, or mood disturbances) [23, 24] . In addition to direct effects of cannabis on cognition, the observed association could also be partly explained by some of the abovementioned conditions for which medicinal use of cannabis is indicated, which themselves may be associated with effects on cognition. The underlying reason for cannabis use (medicinal vs. recreational) unfortunately was not captured as part of data collection, and we were therefore unable to explore this hypothesis further.
We also found multiple metabolic/cardiovascular factors to be associated with cognitive impairment as well as decreased cognitive performance.
Both in the general population and among HIV positives, hypercholesterolaemia, diabetes mellitus type 2, and central obesity have been associated with decreased cognitive function [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
We also found (prior) cardiovascular disease (i.e. angina pectoris, myocardial infarction, or peripheral arterial disease), to be associated with cognitive impairment/ performance. In both the general and HIV-infected population, prior cardiovascular disease and subclinical atherosclerotic disease have been associated with cognitive decline [28, 31, [36] [37] [38] .
In addition, we found albuminuria to be associated with cognitive dysfunction, which is in line with other studies, both in the general and the HIV-infected population [38] [39] [40] .
Interpreting these results, cardiovascular/metabolic factors may substantially contribute to poorer cognitive performance among HIV-infected individuals. Cerebral damage resulting from (micro)vascular disease may therefore importantly contribute towards HIV-associated cognitive impairment. Several neuroimaging studies among HIV-infected individuals have also demonstrated cardiovascular/metabolic factors to be associated with cerebral damage, thereby supporting this hypothesis [41] [42] [43] .
Evidence of renal impairment and past cardiovascular disease (each of which are associated with cognitive dysfunction in our analyses) are likely manifestations of (micro)vascular organ damage in many cases, and may (partly) share pathophysiological mechanisms with cerebral damage.
Presence of depressive symptoms was identified as an additional risk factor for decreased cognitive performance (but not for cognitive impairment). In the general population, depression has been associated with cognitive deficits [44] . Among HIVinfected individuals, depressive symptoms have also been associated with decreased cognitive function [45] , although one study did not report an association between cognitive function and depressive symptoms [46] .
We also found severity of prior immune deficiency, as reflected in a lower nadir CD4 þ cell count, to be associated with decreased cognitive performance, which is also consistent with the earlier findings [12, [47] [48] [49] .
Although HIV infection is known to cause immune deficiency by depleting CD4 þ cells, it is also associated with activation of the immune system and inflammation. This is partly driven by depletion of CD4 þ cells within the intestinal mucosa resulting in increased permeability and translocation of microbial products across the mucosa. This results in stimulation of both the innate and adaptive immune systems that persists, albeit at a reduced level, among cART-treated HIV-infected patients with suppressed viraemia [50, 51] .
Atherosclerosis and cardiovascular disease are also closely related to immune activation and inflammation and have been shown to be highly prevalent among HIV-infected individuals, as is the case for many cardiovascular/ metabolic risk factors (such as dyslipidemia, smoking, and central obesity) [52] . Immune activation and inflammation may therefore contribute to cognitive impairment in a direct manner, but also indirectly, by the association with vascular damage and cerebral small vessel disease.
Three factors were identified as risk factors for decreased cognitive performance, but not for cognitive impairment as a dichotomous outcome: having an above-normal waist-to-hip ratio, presence of depressive symptoms, and a lower nadir CD4 þ cell count. This discrepancy might very well be explained by reduced statistical power when using cognitive impairment as a dichotomous outcome measure instead of cognitive performance as a continuous outcome measure.
In conclusion, our results indicate that reduced cognitive performance in HIV-1-infected men with sustained suppressed viraemia on cART is likely the result of a multifactorial process, in which not only HIV-associated factors, such as having experienced more severe immune deficiency, but also cardiovascular/metabolic factors, cannabis use, and depressive symptoms are key contributors. These are likely to gain increased importance as the population of people living with HIV continues to age. None of these funding bodies had a role in the design or conduct of the study, the analysis and interpretation of the results, or the decision to publish.
